TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
| Condition(s) | Lung Cancer, Non-small Cell, Small Cell Lung Cancer, Pleural Mesothelioma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma. |
| Who can participate | Inclusion Criteria: * Cohort A, B and C : * Written Informed consent * Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly. * Agreement to be followed up at a TRACERx EVO site Cohort A: * Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery * Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre) * Primary surgery in keeping with NICE guidelines in (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surg |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University College, London |
| Locations | London, United Kingdom |
| Start date | 2023-12-04 |
| NCT ID | NCT05628376 |
| Official listing | https://clinicaltrials.gov/study/NCT05628376 |